Head-to-head evidence
BBP-398 vs HBI-2376
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: SHP2 · full Non-Small Cell Lung Cancer pipeline
BBP-398
Developed by Navire Pharma, a BridgeBio company
NCT05480865 · Phase 1 · terminated
This was an open-label, unblinded dose-escalation and expansion study without a comparator arm, in only 28 participants, so any tumor-response signal cannot be attributed to the drug combination with confidence. Results have not been posted yet.
HBI-2376
Developed by HUYABIO International, LLC.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05163028 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BBP-398's landscape · HBI-2376's landscape